OTCMKTS:SYNI

Synvista Therapeutics Competitors

$0.0022
0.00 (0.00 %)
(As of 05/21/2021)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
$0.08
Volume444 shs
Average Volume877 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta10.26

Synvista Therapeutics (OTCMKTS:SYNI) Vs. NEVPF, AKAOQ, ACUS, ADTX, AOLS, and AFFY

Should you be buying SYNI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Synvista Therapeutics, including Abliva AB (publ) (NEVPF), Achaogen (AKAOQ), Acusphere (ACUS), ADiTx Therapeutics (ADTX), Aeolus Pharmaceuticals (AOLS), and Affymax (AFFY).

Abliva AB (publ) (OTCMKTS:NEVPF) and Synvista Therapeutics (OTCMKTS:SYNI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares Abliva AB (publ) and Synvista Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abliva AB (publ)$10,000.003,163.26$-8,150,000.00N/AN/A
Synvista TherapeuticsN/AN/AN/AN/AN/A

Synvista Therapeutics has lower revenue, but higher earnings than Abliva AB (publ).

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Abliva AB (publ) and Synvista Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abliva AB (publ)0000N/A
Synvista Therapeutics0000N/A

Profitability

This table compares Abliva AB (publ) and Synvista Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abliva AB (publ)N/A-54.20%-49.31%
Synvista TherapeuticsN/AN/AN/A

Summary

Synvista Therapeutics beats Abliva AB (publ) on 2 of the 3 factors compared between the two stocks.

Achaogen (OTCMKTS:AKAOQ) and Synvista Therapeutics (OTCMKTS:SYNI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Achaogen and Synvista Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achaogen$8.73 million0.14$-186,510,000.00N/AN/A
Synvista TherapeuticsN/AN/AN/AN/AN/A

Synvista Therapeutics has lower revenue, but higher earnings than Achaogen.

Risk and Volatility

Achaogen has a beta of -0.81, suggesting that its share price is 181% less volatile than the S&P 500. Comparatively, Synvista Therapeutics has a beta of 10.26, suggesting that its share price is 926% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Achaogen and Synvista Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Achaogen0000N/A
Synvista Therapeutics0000N/A

Profitability

This table compares Achaogen and Synvista Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AchaogenN/AN/AN/A
Synvista TherapeuticsN/AN/AN/A

Acusphere (OTCMKTS:ACUS) and Synvista Therapeutics (OTCMKTS:SYNI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Acusphere and Synvista Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
Synvista TherapeuticsN/AN/AN/AN/AN/A

Risk and Volatility

Acusphere has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500. Comparatively, Synvista Therapeutics has a beta of 10.26, suggesting that its share price is 926% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Acusphere and Synvista Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
Synvista Therapeutics0000N/A

Profitability

This table compares Acusphere and Synvista Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
Synvista TherapeuticsN/AN/AN/A

Summary

Synvista Therapeutics beats Acusphere on 1 of the 1 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Synvista Therapeutics (OTCMKTS:SYNI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares ADiTx Therapeutics and Synvista Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADiTx TherapeuticsN/AN/A$-9,150,000.00N/AN/A
Synvista TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for ADiTx Therapeutics and Synvista Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADiTx Therapeutics00103.00
Synvista Therapeutics0000N/A

Profitability

This table compares ADiTx Therapeutics and Synvista Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADiTx TherapeuticsN/AN/AN/A
Synvista TherapeuticsN/AN/AN/A

Summary

ADiTx Therapeutics beats Synvista Therapeutics on 1 of the 1 factors compared between the two stocks.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) and Synvista Therapeutics (OTCMKTS:SYNI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Analyst Ratings

This is a breakdown of current recommendations for Aeolus Pharmaceuticals and Synvista Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aeolus Pharmaceuticals0000N/A
Synvista Therapeutics0000N/A

Profitability

This table compares Aeolus Pharmaceuticals and Synvista Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aeolus PharmaceuticalsN/AN/AN/A
Synvista TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Aeolus Pharmaceuticals and Synvista Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A
Synvista TherapeuticsN/AN/AN/AN/AN/A

Risk and Volatility

Aeolus Pharmaceuticals has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Comparatively, Synvista Therapeutics has a beta of 10.26, suggesting that its share price is 926% more volatile than the S&P 500.

Summary

Synvista Therapeutics beats Aeolus Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Synvista Therapeutics (OTCMKTS:SYNI) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Synvista Therapeutics and Affymax, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synvista Therapeutics0000N/A
Affymax0000N/A

Profitability

This table compares Synvista Therapeutics and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Synvista TherapeuticsN/AN/AN/A
AffymaxN/AN/AN/A

Valuation and Earnings

This table compares Synvista Therapeutics and Affymax's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synvista TherapeuticsN/AN/AN/AN/AN/A
AffymaxN/AN/AN/AN/AN/A

Risk & Volatility

Synvista Therapeutics has a beta of 10.26, suggesting that its share price is 926% more volatile than the S&P 500. Comparatively, Affymax has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500.

Summary

Synvista Therapeutics beats Affymax on 1 of the 1 factors compared between the two stocks.


Synvista Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abliva AB (publ) logo
NEVPF
Abliva AB (publ)
0.5$0.12flat$0.00$10,000.00-2.35Upcoming Earnings
Gap Up
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$0.00$8.73 million0.00Gap Up
Acusphere logo
ACUS
Acusphere
0.0$0.03flat$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.7$2.90flat$0.00N/A0.00Increase in Short Interest
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$0.00N/A0.00High Trading Volume
Decrease in Short Interest
Gap Down
Affymax logo
AFFY
Affymax
0.6$0.06flat$0.00N/A0.00Gap Up
Akari Therapeutics logo
AKTX
Akari Therapeutics
1.4$1.78flat$0.00N/A-3.02Upcoming Earnings
AKRXQ
Akorn
0.1$0.03flat$0.00$682.43 million-0.01
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.08flat$0.00N/A0.00Increase in Short Interest
AOXG
Aoxing Pharmaceutical
0.5$0.01flat$0.00N/A0.00Increase in Short Interest
Gap Up
ARYX
ARYx Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Up
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Down
Bayer Aktiengesellschaft logo
BAYRY
Bayer Aktiengesellschaft
1.2$16.26flat$0.00$47.29 billion-5.89
BSPM
Biostar Pharmaceuticals
0.0$0.12flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.04flat$0.00N/A0.00Gap Down
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million8.40
DDXSQ
Diadexus
0.0$0.00flat$0.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01flat$0.00N/A0.00Increase in Short Interest
Gap Up
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00Gap Up
FTCY
Global Future City
0.5$0.05flat$0.00N/A0.00High Trading Volume
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.45flat$0.00N/A0.00
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Increase in Short Interest
Gap Up
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$6.28flat$0.00$110,000.000.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.62flat$0.00N/A0.00Decrease in Short Interest
Gap Down
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00Gap Down
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00High Trading Volume
Gap Down
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.00flat$0.00N/A0.00
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Decrease in Short Interest
Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Down
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.13flat$0.00N/A0.00Increase in Short Interest
PZRXQ
PhaseRx
0.2$0.02flat$0.00N/A0.00Gap Up
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.04flat$0.00N/A0.00News Coverage
Gap Down
PARD
Poniard Pharmaceuticals
0.5$0.04flat$0.00N/A0.00Gap Up
ROSGQ
Rosetta Genomics
0.0$0.07flat$0.00N/A0.00Increase in Short Interest
Gap Up
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00Increase in Short Interest
Shiseido logo
SSDOY
Shiseido
1.0$74.15flat$0.00$8.63 billion-218.09Increase in Short Interest
Sio Gene Therapies logo
SIOX
Sio Gene Therapies
1.6$2.49flat$0.00N/A-2.96Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00Gap Up
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01flat$0.00N/A0.00Gap Down
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.02flat$0.00N/A0.00Decrease in Short Interest
Targeted Medical Pharma logo
TRGM
Targeted Medical Pharma
0.8$0.02flat$0.00N/A0.00Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.03flat$0.00N/A0.00Gap Up
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Up
Tiziana Life Sciences logo
TLSA
Tiziana Life Sciences
1.2$2.49flat$0.00N/A0.00Upcoming Earnings
Decrease in Short Interest
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.09flat$0.00$6.81 million-4.56Decrease in Short Interest
Gap Up
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.